---
document_datetime: 2023-09-21 20:29:45
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/pegintron-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: pegintron-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 1.1457314
conversion_datetime: 2025-12-19 22:44:49.926225
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION

For procedures finalised after 7 May 2002 please refer to module 8B.

· EMEA/H/C/280/II/01 The  Marketing  Authorisation  Holder  submitted  on  28 th July  2000  an application  for  a  Type  II  variation  (Use  in  combination  with  ribavirin  for  the  treatment  of chronic Hepatitis C), pursuant to Article 4 of Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended.  A positive opinion was given on 14 th December 2000 and a Decision by the European Commission on 26 March 2001. · EMEA/H/C/280/II/02 A type II variation was started on 30 th June 2000 (Improvement of the manufacturing process), pursuant to Article 6 of Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended.  A positive opinion was adopted by the CPMP on 28 August 2000 with a European Commission Decision on 14 th September 2000. · EMEA/H/C/280/I/03 A Type I following Type II variation (Minor change of  manufacturing process  of  the  active  substance),  pursuant  to  Article  4  of  Commission  Regulation  (EC)  No. 542/95 of 10 March 1995, as amended was started on 30 th June 2000.  The Head of the Human Medicines Evaluation Unit signed a positive notification on 28 August 2000. · EMEA/H/C/280/I/04 A  Type  I  (point  20)  variation  (Extension  of  shelf  life  from  24  to  36 months), pursuant to Article 4 of Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended was started on 17 th July 2000.  The Head of Sector Quality of Medicines signed a positive notification on 11 August 2000 and the European Commission granted a Commission Decision on 16 November 2000. · EMEA/H/C/280/I/05 A Type I (point 30) variation (Additional pack sizes), pursuant to Article 4 of Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended was started on 17 th July 2000.  The Head of Sector Quality of Medicines signed a positive notification on 10 August 2000 and the European Commission granted a Commission Decision on 16 November 2000. · EMEA/H/C/280/I/06 -10 Five Type I (point 14) variations (Change in the specifications of the active  substance),  pursuant  to  Article  4  of  Commission  Regulation  (EC)  No.  542/95  of  10 March  1995,  as  amended  were  started  on  19 th September  2000.    The  Head  of  the  Human Medicines Evaluation Unit signed a positive notification on 19 October 2000. · EMEA/H/C/280/I/11 A Type I (point 24) variation (Change in the test procedure of the active substance), pursuant to Article 4 of Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended was started on 19 th September 2000.  The Head of the Human Medicines Evaluation Unit signed a positive notification on 19 December 2000. · EMEA/H/C/280/I/12 A Type I (point 24) variation (Change in the test procedure of the active substance), pursuant to Article 4 of Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended was started on 29 th November 2000.  The Head of the Human Medicines Evaluation Unit signed a positive notification on 4 January 2001. · EMEA/H/C/280/I/16 A Type I variation, No. 20a (Extension of shelf life), pursuant to Article 4 of Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended was started on3rd May 2001.  The Head of Sector Quality of Medicines signed a positive notification on 1 st June 2001. Medicinal product no longer authorise

<div style=\"page-break-after: always\"></div>

Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below:

| Scope                                                                            | Application number   | Type of modification 1   | Notification/ Opinion issued on 2   | Commission Decision Issued/amen ded on   |
|----------------------------------------------------------------------------------|----------------------|--------------------------|-------------------------------------|------------------------------------------|
| Quality changes (TSE compliance)                                                 | II/0013              | II                       | 20.09.01                            | 15.10.01                                 |
| Extension of shelf-life or retest period of the active substance                 | I/0017               | I                        | 28.01.02                            | 04.03.02                                 |
| Change in specifications of active substance                                     | I/0018               | I                        | 26.03.02                            |                                          |
| Line Extension: Powder and solvent for solution for injection in pre- filled pen | X/0014               | X                        | 20.09.01                            | 06.02.02                                 |
| Update of SPC and PL                                                             | II/0015              | II                       | 15.11.01                            | 07.05.02                                 |

T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 November 1996.

Change in specifications of active substance Line Extension: Powder and solvent for solution for injection in prefilled pen Update of SPC and PL II/0015 II 15.11.01 07.05.02 1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II application. Medicinal product no longer authorised

N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992.

2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date. The Commission Decision will be amended accordingly.